# Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

> **NCT00738881** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib Hydrochloride
- **DRUG:** Pemetrexed Disodium

## Key facts

- **NCT ID:** NCT00738881
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2011-12
- **Final completion:** 2014-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2015-10-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738881, "Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00738881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*